Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.


Advances in Transfusion Safety

Meeting, San Francisco, Calif., March 1999

Society/Societies: International Alliance for Biological Standardization (IABS)  () 
Editor(s): Brown F. (Greenport, N.Y.) 
Vyas G.N. (San Francisco, Calif.) 

Status: available   
Publication year: 2000
Buy this book
Print Version: CHF 240.00, EUR 224.00, USD 282.00
The final prices may differ from the prices shown due to specifics of VAT rules, postage and handling.
Order this title

You already have online access to this title. If you would like to buy a personal digital or print copy, please click here.

This book belongs to
Developments in Biologicals , Vol. 102
XII + 252 p., 39 fig., 59 tab., soft cover, 2000
Status: available   
ISSN: 1424-6074
e-ISSN: 1662-2960

Our current understanding of the molecular mechanisms underlying host-parasite interaction in the establishment of persistent infections transmitted through blood transfusion permits us to develop strategies for their prevention. Because of rigorous screening to prevent transmission of blood-borne infections, the transfusion of blood and blood products has already achieved an unprecedented level of safety. The «window period» viraemia can be further reduced by screening donated blood with nucleic acid testing (NAT) technology now being introduced in Europe and the U.S.A. Both immunological and virological risks of transfusion can be reduced by photodecontamination and universal leukofiltration performed at the blood processing facilities. Unquestionably, progressive improvements in transfusion safety leads to an escalation in the cost of our blood supply; therefore, cost effectiveness, quality control, and regulatory issues have become topics of considerable importance in responding to our society's expectation of risk-free hemotherapy.